Skip to main page content

FDA's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

U.S. Department of Health and Human Services

U.S. Food and Drug Administration

Protecting and Promoting Your Health

FDA NEWS RELEASE

For Immediate Release: Dec. 23, 2013
Media Inquiries: Jennifer Rodriguez, 301-796-8232, jennifer.rodriguez@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA,
FDA approves Tretten to treat rare genetic clotting disorder
The U.S. Food and Drug Administration today approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.
 
Congenital Factor XIII deficiency is an extremely rare genetic disorder. Patients with this deficiency do not make enough Factor XIII, a protein that circulates in the blood and is important for normal clotting. Factor XIII is composed of two subunits, A and B. Factor XIII deficiency is usually caused by a deficiency of the A-subunit.
 
“The approval of this product provides another therapeutic option for the prevention of bleeding in patients with Factor XIII A-subunit deficiency,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Without treatment, people with this rare condition are at risk for serious and life-threatening bleeding.”
 
Tretten is a recombinant analogue of the human Factor XIII A-subunit that is produced in yeast cells and then further purified. It is a sterile freeze-dried-powder to be reconstituted with diluent and injected intravenously. Tretten can be administered by a physician or be self-administered.
 
The effectiveness of Tretten was studied in 77 patients with congenital Factor XIII A-subunit deficiency. Tretten was effective in preventing bleeding in 90 percent of the patients when given monthly. Some of the side effects reported in this study were headache, pain in the extremities and pain at injection site. No individual in the trial developed abnormal clots.
 
Tretten received orphan-drug designation for this use by the FDA because it is intended for treatment of a rare disease or condition.
 
Tretten is made by Novo Nordisk A/S, Denmark, and is distributed by Novo Nordisk, Inc., USA.
 
For more information:
 
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Page Last Updated: 12/23/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

News Source : Skip to main page content

Copy this html code to your website/blog to embed this press release.